Nanobiotix (NANO) Jefferies London Healthcare Conference 2024 summary

Company vision and technology platforms

• Focus on nanophysics-based therapeutics to reduce variability and enable universal application across millions of patients.

• Three platforms: oncology (licensed to J&J), CNS disorders, and a new therapeutic design platform to be detailed later.

NBTXR3 strategy and clinical rationale

• Targeting locally advanced disease settings to maximize impact and address unmet needs before metastasis occurs.

• Radiation therapy is used in over 60% of cancer patients; NBTXR3 aims to enhance its efficacy and safety.

• NBTXR3 is a one-time injectable nanocrystal drug that amplifies radiation effects and triggers immune response.

Partnership and clinical development

• J&J selected as partner for global commercialization and development due to shared vision and capabilities.

• NBTXR3 is in a global phase III trial (312) for locally advanced head and neck cancer, targeting frail elderly patients.

• Phase III design: 500 patients, primary endpoint is progression-free survival, with final recruitment expected H1 2026.